Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title Hits
11 Mar 2010 BioInvent and Human Genome Sciences Announce Collaboration to Co-develop and Commercialize Therapeutic Antibodies 9
11 Mar 2010 Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer 13
09 Mar 2010 Successful Development of Broad Spectrum Human Monoclonal Antibodies Against Major Influenza Viruses (H1N1 and H5N1) 49
08 Mar 2010 Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold 76
08 Mar 2010 Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients 43
04 Mar 2010 CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin Therapy 70
02 Mar 2010 FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients 133
01 Mar 2010 GTC Provides Update on TG20 Monoclonal Antibody Targeting CD20 94
01 Mar 2010 arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies 2
24 Feb 2010 Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria 61
24 Feb 2010 Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer 98
22 Feb 2010 Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva(R) in Patients with Non-Small Cell Lung Cancer 73
22 Feb 2010 Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint 88
18 Feb 2010 VEGF Trap-Eye Shows Positive Results in Phase II Study in Patients with Diabetic Macular Edema 162
18 Feb 2010 FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia 79
16 Feb 2010 Thallion Pharmaceuticals and LFB biotechnologies sign definitive agreement to develop and commercialize treatment for E. Coli (STEC) infection 101
16 Feb 2010 New High Purity Immunoglobulin Enters Phase III in Europe and the US 88
11 Feb 2010 ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE 149
10 Feb 2010 Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day 80
09 Feb 2010 Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases 100
09 Feb 2010 XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients 88
09 Feb 2010 Phase I Trial Commences Treating Patients with Pancreatic and Colorectal Cancer Using Novel Monoclonal Antibody 102
08 Feb 2010 AnaptysBio Announces Strategic Collaboration with Merck & Co., Inc. 21
08 Feb 2010 Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche 35
05 Feb 2010 TenX Biopharma Licenses Zanolimumab From Genmab 114
04 Feb 2010 BTG Receives First European Regulatory Approval for DigiFab 42
03 Feb 2010 Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma 145
02 Feb 2010 Compugen Discovers Novel Protein for Treatment of Autoimmune Diseases 88
02 Feb 2010 Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 117
02 Feb 2010 Cambridge-Based Biotech Isogenica Announces New Partnership with Phylogica 78
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1693

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics